Plasma microRNA 210 levels correlate with sensitivity to trastuzumab and tumor presence in breast cancer patients
Eun‐Jung Jung(The University of Texas MD Anderson Cancer Center), George A. Călin(The University of Texas MD Anderson Cancer Center), Libero Santarpia(Humanitas University), Robert C. Bast(The University of Texas MD Anderson Cancer Center), Aman U. Buzdar(The University of Texas MD Anderson Cancer Center), Xiao‐Feng Le(The University of Texas MD Anderson Cancer Center), Erica Moretti(Hospital of Prato), Francisco J. Esteva(Northwell Health), Ju‐Yeon Kim(Gyeongsang National University), Soon‐Tae Park(Gyeongsang National University Hospital), Angelo Di Leo(Hospital of Prato), Lajos Pusztai(Yale University)
Cited by 291
Related Papers
Pembrolizumab for Early Triple-Negative Breast Cancer
|New England Journal of Medicine|2020|3.1k
PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients
|Cancer Cell|2004|1.9k
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
|Annals of Oncology|2015|1.8k
Reactivity of a monoclonal antibody with human ovarian carcinoma.
|Journal of Clinical Investigation|1981|1.7k
Measurement of Residual Breast Cancer Burden to Predict Survival After Neoadjuvant Chemotherapy
|Journal of Clinical Oncology|2007|1.6k